216 related articles for article (PubMed ID: 23723069)
1. Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3).
Rafidi H; Mercado F; Astudillo M; Fry WH; Saldana M; Carraway KL; Sweeney C
J Biol Chem; 2013 Jul; 288(30):21593-605. PubMed ID: 23723069
[TBL] [Abstract][Full Text] [Related]
2. In vivo analysis of Lrig genes reveals redundant and independent functions in the inner ear.
Del Rio T; Nishitani AM; Yu WM; Goodrich LV
PLoS Genet; 2013; 9(9):e1003824. PubMed ID: 24086156
[TBL] [Abstract][Full Text] [Related]
3. Vertebrate Lrig3-ErbB interactions occur in vitro but are unlikely to play a role in Lrig3-dependent inner ear morphogenesis.
Abraira VE; Satoh T; Fekete DM; Goodrich LV
PLoS One; 2010 Feb; 5(2):e8981. PubMed ID: 20126551
[TBL] [Abstract][Full Text] [Related]
4. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.
Laederich MB; Funes-Duran M; Yen L; Ingalla E; Wu X; Carraway KL; Sweeney C
J Biol Chem; 2004 Nov; 279(45):47050-6. PubMed ID: 15345710
[TBL] [Abstract][Full Text] [Related]
5. The LRIG family: enigmatic regulators of growth factor receptor signaling.
Simion C; Cedano-Prieto ME; Sweeney C
Endocr Relat Cancer; 2014; 21(6):R431-43. PubMed ID: 25183430
[TBL] [Abstract][Full Text] [Related]
6. LMO7 and LIMCH1 interact with LRIG proteins in lung cancer, with prognostic implications for early-stage disease.
Karlsson T; Kvarnbrink S; Holmlund C; Botling J; Micke P; Henriksson R; Johansson M; Hedman H
Lung Cancer; 2018 Nov; 125():174-184. PubMed ID: 30429017
[TBL] [Abstract][Full Text] [Related]
7. LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor.
Wang Y; Poulin EJ; Coffey RJ
Br J Cancer; 2013 May; 108(9):1765-70. PubMed ID: 23558895
[TBL] [Abstract][Full Text] [Related]
8. HYPOTHESIS: Do LRIG Proteins Regulate Stem Cell Quiescence by Promoting BMP Signaling?
Herdenberg C; Hedman H
Stem Cell Rev Rep; 2023 Jan; 19(1):59-66. PubMed ID: 35969315
[TBL] [Abstract][Full Text] [Related]
9. LRIG and cancer prognosis.
Lindquist D; Kvarnbrink S; Henriksson R; Hedman H
Acta Oncol; 2014 Sep; 53(9):1135-42. PubMed ID: 25180912
[TBL] [Abstract][Full Text] [Related]
10. Lrig1 and Lrig3 cooperate to control Ret receptor signaling, sensory axonal growth and epidermal innervation.
De Vincenti AP; Alsina FC; Ferrero Restelli F; Hedman H; Ledda F; Paratcha G
Development; 2021 Aug; 148(16):. PubMed ID: 34338291
[TBL] [Abstract][Full Text] [Related]
11. Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.
Torigoe H; Yamamoto H; Sakaguchi M; Youyi C; Namba K; Sato H; Shien K; Soh J; Suzawa K; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
Carcinogenesis; 2018 May; 39(5):719-727. PubMed ID: 29546323
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) in HP75 pituitary adenoma cell line.
Guo D; Han L; Shu K; Chen J; Lei T
J Huazhong Univ Sci Technolog Med Sci; 2007 Feb; 27(1):91-4. PubMed ID: 17393120
[TBL] [Abstract][Full Text] [Related]
13. Expression of LRIG1 and LRIG3 correlates with human papillomavirus status and patient survival in cervical adenocarcinoma.
Muller S; Lindquist D; Kanter L; Flores-Staino C; Henriksson R; Hedman H; Andersson S
Int J Oncol; 2013 Jan; 42(1):247-52. PubMed ID: 23165628
[TBL] [Abstract][Full Text] [Related]
14. LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers.
Malik U; Javed A
Curr Cancer Drug Targets; 2017; 17(1):3-16. PubMed ID: 27628597
[TBL] [Abstract][Full Text] [Related]
15. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy.
Shattuck DL; Miller JK; Laederich M; Funes M; Petersen H; Carraway KL; Sweeney C
Mol Cell Biol; 2007 Mar; 27(5):1934-46. PubMed ID: 17178829
[TBL] [Abstract][Full Text] [Related]
16. A protein interaction network centered on leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) regulates growth factor receptors.
Faraz M; Herdenberg C; Holmlund C; Henriksson R; Hedman H
J Biol Chem; 2018 Mar; 293(9):3421-3435. PubMed ID: 29317492
[TBL] [Abstract][Full Text] [Related]
17. Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors.
Guo D; Nilsson J; Haapasalo H; Raheem O; Bergenheim T; Hedman H; Henriksson R
Acta Neuropathol; 2006 Mar; 111(3):238-46. PubMed ID: 16532360
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of LRIG proteins in meningiomas: correlation between estrogen receptor status and LRIG expression.
Ghasimi S; Haapasalo H; Eray M; Korhonen K; Brännström T; Hedman H; Andersson U
J Neurooncol; 2012 Jul; 108(3):435-41. PubMed ID: 22484910
[TBL] [Abstract][Full Text] [Related]
19. Expression of LRIG1, a Negative Regulator of EGFR, Is Dynamically Altered during Different Stages of Gastric Carcinogenesis.
Yu S; Yang M; Lim KM; Cho Y; Kim H; Lee K; Jeong SH; Coffey RJ; Goldenring JR; Nam KT
Am J Pathol; 2018 Dec; 188(12):2912-2923. PubMed ID: 30248341
[TBL] [Abstract][Full Text] [Related]
20. LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells.
Yokdang N; Hatakeyama J; Wald JH; Simion C; Tellez JD; Chang DZ; Swamynathan MM; Chen M; Murphy WJ; Carraway Iii KL; Sweeney C
Oncogene; 2016 Jun; 35(22):2932-47. PubMed ID: 26387542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
